Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

By sjmartinez • August 15, 2024

Rastogi A, Collins A, Kelepouris E, Kotzker W, Middleton JP, Rajpal M, Roy-Chaudhury P, Chertow GM. Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241259905. doi: 10.1177/21501319241259905. PMID: 39143759.

Tags: Chronic kidney disease, consensus, KDIGO, Nephrology, Publications, SGLT2 inhibitor, treatment algorithm

Favorable Adherence and Tolerability of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in Kidney Transplant Recipients Aged 65 y or Older: Findings From a Randomized, Phase 3 Trial

Bunnapradist S, Vincenti F, Witzke O, Schneeberger S, Nguyen MH, Broyde N, Gilbert CL, Haber B. Favorable Adherence and Tolerability of Letermovir Versus Valganciclovir for[...]

Online hemodiafiltration for kidney failure: guidance and best clinical practice recommendations from the Italian Society of Nephrology

Strippoli GFM, Pellegrino G, Hegbrant J, Fabbrini P, Lentini PLM, Aucella F, Panichi V, Gallieni M, Canaud B, Davenport A, Ortiz A, Ramos R, Malyszko[...]

A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers

Zhang K, Lampridis S, Simone CB 2nd, Negoi I, Peng Y, Shang B, Lin Y, Cheng Y, Yang F, Shelat VG, Kalantar-Zadeh K. A literature[...]